AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.
|Articles|December 10, 2009
Scottish Life Science Sector Receives Euro 26 Million Boost
11 December.
Advertisement
The announcement of a new 10,000 sq m bio-incubator for the Edinburgh BioQuarter confirms the latest £24 million (E26.4 million) investment in the Scottish life sciences cluster.
The facility will be jointly funded by the UK Department for Business Innovation and Skills through the Strategic Investment Fund and Scottish Enterprise. Welcoming the announcement, Lena Wilson, chief executive of Scottish Enterprise, said: "The BioQuarter is one of the largest projects of its type in Europe and this funding will allow the partners to cement Scotland's position as one of the most dynamic locations for life sciences globally."
The bio-incubator is targeted at start-up and spin-out biotechnology companies, and will help to create 200 jobs in Edinburgh over the next five years. It will offer access to high-cost specialized equipment, advice, mentoring and expertise to support successful product development.
Advertisement
Related to this article
Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses.
Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Advertisement
Advertisement
Trending on PharmExec
1
CagriSema Tops Eli Lilly's Tirzepatide for Weight Loss in Late-Stage Diabetes Trial: Report
2
Understanding the Latest with MFN Pricing and What It Means to Pharma
3
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
4
Roundup: AbbVie & Lambic Enter Ai Drug Discovery Collaboration, Telix Merges with ITM
5